Alcyone Therapeutics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$160M
- Investors
-
1
Alcyone Therapeutics General Information
Description
Developer of neural intervention technology designed to treat neurological conditions. The company's technology is based on an engineered combination of micro-fabrication technologies and advanced biomedical engineering, with a core product focus on targeted drug therapy and hydrocephalus, enabling patients with chronic neuropathological conditions to receive improved treatment.
Contact Information
Website
alcyonetx.com(Operating Subsidiary)
Corporate Office
- 116 John Street
- Suite 300
- Lowell, MA 01852
- United States
Corporate Office
- 116 John Street
- Suite 300
- Lowell, MA 01852
- United States
Alcyone Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 07-Nov-2025 | $160M | Completed | Generating Revenue | ||
| 10. Later Stage VC (Series F) | 03-Apr-2025 | Completed | Generating Revenue | |||
| 9. Grant | 31-Dec-2021 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series E) | 08-Jun-2021 | Completed | Generating Revenue | |||
| 7. Debt - PPP | 27-Apr-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 17-Jan-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 24-Dec-2015 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 13-Jan-2014 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A1) | 20-May-2013 | $1M | $2.84M | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 27-Mar-2012 | $1.84M | $1.84M | Completed | Generating Revenue |
Alcyone Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E-1 | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 1,678,429 | $0.000001 | 6% | $0.43 | $0.43 | 1x | $0.43 | 2.44% |
| Series A | 3,834,881 | $0.000001 | 6% | $0.37 | $0.37 | 1x | $0.37 | 5.57% |
Alcyone Therapeutics Comparisons
Industry
Financing
Details
Alcyone Therapeutics Competitors (20)
One of Alcyone Therapeutics’s 20 competitors is Orgenesis, a Corporation company based in Germantown, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orgenesis | Corporation | Germantown, MD | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| Psy Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Hua Medicine | Formerly VC-backed | Pudong, China |
Alcyone Therapeutics Patents
Alcyone Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025249271-A1 | Methods and compositions for retinal gene therapy | Pending | 02-Apr-2024 | ||
| WO-2025212772-A1 | Methods and compositions for retinal gene therapy | Pending | 02-Apr-2024 | ||
| JP-2024519889-A | Fluid delivery system and method of treatment | Pending | 19-May-2021 | ||
| CA-3219514-A1 | Fluid delivery systems and methods of treatment | Pending | 19-May-2021 | ||
| WO-2022246042-A1 | Fluid delivery systems and methods of treatment | Inactive | 19-May-2021 | A61K31/713 |
Alcyone Therapeutics Signals
Alcyone Therapeutics Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Harbor Light Capital Partners | Venture Capital | Minority | ||
| National Aeronautics and Space Administration | Government | |||
| Pimlico Pond Investments | Family Office | Minority | ||
| RTW Investments | Hedge Fund | Minority | ||
| Thornapple River Capital | Venture Capital | Minority |
Alcyone Therapeutics FAQs
-
When was Alcyone Therapeutics founded?
Alcyone Therapeutics was founded in 2010.
-
Where is Alcyone Therapeutics headquartered?
Alcyone Therapeutics is headquartered in Lowell, MA.
-
What is the size of Alcyone Therapeutics?
Alcyone Therapeutics has 12 total employees.
-
What industry is Alcyone Therapeutics in?
Alcyone Therapeutics’s primary industry is Drug Discovery.
-
Is Alcyone Therapeutics a private or public company?
Alcyone Therapeutics is a Private company.
-
What is the current valuation of Alcyone Therapeutics?
The current valuation of Alcyone Therapeutics is .
-
What is Alcyone Therapeutics’s current revenue?
The current revenue for Alcyone Therapeutics is .
-
How much funding has Alcyone Therapeutics raised over time?
Alcyone Therapeutics has raised $71.8M.
-
Who are Alcyone Therapeutics’s investors?
Harbor Light Capital Partners, National Aeronautics and Space Administration, Pimlico Pond Investments, RTW Investments, and Thornapple River Capital have invested in Alcyone Therapeutics.
-
Who are Alcyone Therapeutics’s competitors?
Orgenesis, Neurogene, Psy Therapeutics, Voyager Therapeutics, and Hua Medicine are some of the 20 competitors of Alcyone Therapeutics.
-
When was Alcyone Therapeutics acquired?
Alcyone Therapeutics was acquired on 07-Nov-2025.
-
Who acquired Alcyone Therapeutics?
Alcyone Therapeutics was acquired by Biogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process